Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term rhIGF-1 (mecasermin) in children with growth hormone insensitivity syndrome
2025-000222-34Phase 2
- Sponsor
- Ipsen
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mecasermin in growth hormone insensitivity (GHIS), insulin-like growth factor 1 deficiency and Short stature due to endocrine disorder, sponsored by Ipsen. Primary endpoint: Annualized Height Velocity.
02
Drugs
mecasermin
03
Conditions
growth hormone insensitivity (GHIS)insulin-like growth factor 1 deficiencyShort stature due to endocrine disorder
Beyond the preview
Go deeper on 2025-000222-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000222-34.